Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 clinical study of Debio 1453

Next Previous
Trial Profile

Phase 1 clinical study of Debio 1453

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Debio 1453 (Primary)
  • Indications Neisseria infections
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 02 Jun 2025 New trial record
  • 28 May 2025 According to CARB-X media release, company was awarded further funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator. The newly awarded grant is projected to amount to 12.3 million USD broken down into two parts. Part 1 will contribute to further advancing Debio 1453 to phase 1 first-in-human evaluation. Part 2 of the grant will be considered by CARB-X based upon the achievement of predetermined milestones.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top